GSK Ups Legal Reserve, May Break Pfizer's Settlement Record
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithkline expects to record a $3.4 billion legal charge relating to a government investigation of its marketing practices and Avandia product liability suits.
You may also be interested in...
GSK’s Deal With DoJ Is Fourth In Eight Years; Exec Liability Uncertain
GlaxoSmithKline PLC’s toughest negotiations this year have been with the federal government.
GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit
If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.
GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit
If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.